A pilot study for augmenting atomoxetine with methylphenidate: safety of concomitant therapy in children with attention-deficit/hyperactivity disorder

Table 3 Effect sizes for Efficacy Outcome Measures Across Treatment Phases

Measures	ATX +MPH (n= 9)	ATX + PBO (excl. ER) (n= 8)	ALL ATX + PBO (n= 12)
ADHD RS-IV-Parent:Inv T score
Overall effect	1.3***	1.2**	1.3***
Incremental effect	0.05	0.18	0.03
WREMB-AM
Overall effect	0.60	0.82	0.79
Incremental effect	0.43	0.07	0.11
WREMB-PM
Overall effect	0.56	0.70	0.94*
Incremental effect	0.33	0.01	0.02
CGI-Severity
Overall effect	1.3*	1.3**	1.4**
Incremental effect	.34	.38	0.25
Conner Parent Rating Scale
Overall effect	1.2*	0.80**	0.98***
Incremental	0.18	0.09	0.07

Key: ER, Early responders; ADHD-RS-IV-Parent:Inv, ADHD Rating Scale Parent Report Investigator Rated; WREMB, Weekly Ratings Evening and Morning Behaviors. Note: Overall effect size was from baseline to study end-point (10 weeks ATX treatment); Incremental effect size from double-blind randomization to study end-point (6 weeks augmentation treatment).
*P ≤ .05, within group; **P ≤ .01, within group; *** P ≤ .001, within group from baseline

ISSN: 1753-2000